Vaccinex, Inc. financial data

Symbol
VCNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1895 Mount Hope Ave, Rochester, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 79.3 % -31.1%
Return On Equity 1.93K %
Return On Assets -408 % +14.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.6M shares -79.2%
Common Stock, Shares, Outstanding 2.6M shares -46.5%
Entity Public Float 10.4M USD -58.7%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 2.03M shares +529%
Weighted Average Number of Shares Outstanding, Diluted 2.03M shares +529%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 52K USD +160%
Research and Development Expense 13.8M USD -18.8%
General and Administrative Expense 6.96M USD +1.49%
Costs and Expenses 20.7M USD -13%
Operating Income (Loss) -20.3M USD +11.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18.6M USD +15.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.6M USD +15.6%
Earnings Per Share, Basic 8.13 USD/shares +81.4%
Earnings Per Share, Diluted 8.13 USD/shares +81.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.91M USD +2188%
Accounts Receivable, after Allowance for Credit Loss, Current 985K USD +5.57%
Assets, Current 4.76M USD +116%
Property, Plant and Equipment, Net 82K USD -50%
Operating Lease, Right-of-Use Asset 15K USD -92%
Assets 4.85M USD +89.8%
Accounts Payable, Current 4.87M USD +15.1%
Employee-related Liabilities, Current 238K USD -17.1%
Accrued Liabilities, Current 1.2M USD -36.7%
Contract with Customer, Liability, Current 51K USD
Liabilities, Current 6.18M USD -2.94%
Operating Lease, Liability, Noncurrent 21K USD -88.8%
Liabilities 6.18M USD -3.92%
Retained Earnings (Accumulated Deficit) -355M USD -5.52%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.32M USD +65.9%
Liabilities and Equity 4.85M USD +89.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.63M USD +8.1%
Net Cash Provided by (Used in) Financing Activities 6.07M USD +200%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.6M shares -46.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44M USD
Deferred Tax Assets, Valuation Allowance 110M USD +6.6%
Deferred Tax Assets, Gross 110M USD +6.6%
Operating Lease, Liability 15K USD -92%
Depreciation 103K USD -24.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -18.6M USD +15.6%
Property, Plant and Equipment, Gross 7.25M USD +0.3%
Operating Lease, Liability, Current 15K USD -91%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 87 USD -98.9%
Deferred Tax Assets, Operating Loss Carryforwards 78.5M USD +3.6%
Preferred Stock, Shares Issued 10 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 45.1K USD 0%
Preferred Stock, Shares Outstanding 10 shares
Operating Leases, Future Minimum Payments, Due in Two Years 331K USD +128%
Share-based Payment Arrangement, Expense 388K USD -22.7%
Operating Leases, Future Minimum Payments Due 15K USD -92.3%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares